Hepatitis C
Conditions
Keywords
Antimetabolites, Virus Diseases, Anti-Infective Agents, RNA Virus Infections, Digestive System Diseases, Flaviviridae Infections, Antineoplastic Agents, Therapeutic Uses, Antiviral Agents, Molecular Mechanisms of Action, Pharmacologic Actions
Brief summary
The purposes of the PLUS study were to confirm the safety and tolerability of two doses of LocteronTM (320 ug and 640 ug) dosed over four weeks in patients who had failed prior anti-HCV therapies (Panels A and B), and then to continue to study the safety, tolerability, and preliminary efficacy of the same two doses of LocteronTM (320 ug and 640 ug) in treatment-naïve genotype 1 HCV patients when Locteron dosed over 12 weeks (Panel C). All subjects were also to receive oral daily weight-based ribavirin.
Detailed description
Panels A and B of the PLUS study were designed to assess the safety and tolerability, pharmacokinetics, and viral kinetics over four weeks of two doses of Locteron™ (230 ug and 640 ug) given every two weeks in comparison with PegIntron® given weekly in treatment-experienced subjects with chronic hepatitis C of any genotype who were co-administered weight-based oral ribavirin. The two cohorts of 16 subjects each in Panels A and B consisted of subjects who had failed prior interferon therapy. In Panel A, 8 subjects were randomized to and completed 4 weeks of treatment with 320 μg Locteron™ and 8 subjects were randomized to and completed 4 weeks of treatment with 1.5 ug/kg PegIntron®. In Panel B, 8 subjects were randomized to and completed 4 weeks of treatment with 640 μg Locteron™ and 8 subjects were randomized to and completed 4 weeks of treatment with 1.5 ug/kg PegIntron®. When the results of Panel A and Panel B were known, conduct of Panel C for 12 weeks in treatment-naive patients with chronic genotype-1 HCV was considered unnecessary and cancelled, and an entirely new study was begun instead.
Interventions
OTHERLocteron (controlled-release interferon alpha 2b)
biological+device, bi-weekly subcutaneous injections for 4-12 weeks, 160 mcg per injection
BIOLOGICALpegylated IFNa2b
biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg
Sponsors
Biolex Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Evidence of chronic hepatitis C * Positive HCV RNA test with a level \>= 1 x 104 IU/mL (by RT-PCR)
Exclusion criteria
* Decompensated Liver Disease * Positive test for serum antibodies to the human immunodeficiency virus (HIV), hepatitis A (HAV-IgM), o hepatitis B (HBV- +Hepatitis B surface antigen) * A history of severe psychiatric disease, including major depression * A history of immunologically-mediated disease, COPD, severe asthma, severe cardiac disease, active cancer or cancer within last 5 years, seizures within the past 5 years or epilepsy, solid organ or bone marrow transplant, uncontrolled thyroid disease, or clinically significant retinopathy * Pregnant or lactating females
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess in subjects with chronic hepatitis C the safety and tolerability of Locteron in comparison with PEG-Intron. | 7 months (4 weeks of treatment, 6 months of follow up) |
Secondary
| Measure | Time frame |
|---|---|
| To assess in subjects with chronic hepatitis C receiving a weight-based oral daily dose of ribavirin: • The PK profile of Locteron (IFNa2b) • The preliminary efficacy of Locteron assessed by serial quantitation of HCV RNA levels | 4 weeks |
Countries
United States
Outcome results
None listed